UK markets open in 3 hours 54 minutes

BioPorto A/S (BIOPOR.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
2.5500+0.0550 (+2.20%)
At close: 04:59PM CET
Full screen
Previous close2.4950
Open2.5000
Bid2.5500 x 0
Ask2.5700 x 0
Day's range2.5000 - 2.6650
52-week range1.0020 - 3.2700
Volume376,487
Avg. volume630,420
Market cap853.434M
Beta (5Y monthly)1.33
PE ratio (TTM)N/A
EPS (TTM)-0.2140
Earnings date09 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • Globe Newswire

    Resolutions of the Extraordinary General Meeting of BioPorto A/S

    November 23, 2022 Announcement no. 17 Resolutions of the Extraordinary General Meeting of BioPorto A/S COPENHAGEN, DENMARK and BOSTON, MA, USA, November 23, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) today held an Extraordinary General Meeting with the following results: Deloitte Statsautoriseret Revisionspartnerselskab, company registration number 33963556, was elected as the Company’s new auditor.The chair of the general meeting, with a right of substitution, was

  • Globe Newswire

    Correction: BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

    November 10, 2022 Announcement no. 16 BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration COPENHAGEN, DENMARK and BOSTON, MA, USA, November 10, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) has announced the submission of a De Novo application to the US Food and Drug Administration (FDA) of a neutrophil gelatinase-associated lipocalin (NGAL) test to aid in identifying pediatric patients (≥3 months to <22 years)

  • Globe Newswire

    BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

    November 10, 2022 Announcement no. 16 BioPorto Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration COPENHAGEN, DENMARK and BOSTON, MA, USA, November 10, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) has announced the submission of a De Novo application to the US Food and Drug Administration (FDA) of a neutrophil gelatinase-associated lipocalin (NGAL) test to aid in identifying pediatric patients (≥3 months to <22 years)